| ACE |
= Angiotensin-converting enzyme |
|
IL-18 |
= Interleukin-18 |
| ACEIs |
= Angiotensin-converting enzyme inhibitors |
|
KDIGO |
= Kidney Disease Improving Global Outcomes |
| ACx |
= Aortic cross-clamping |
|
KIM-1 |
= Kidney injury molecule-1 |
| AKI |
= Acute kidney injury |
|
L-FABP |
= Liver fatty-acid binding protein |
| AKIN |
= Acute Kidney Injury Network |
|
MCPB |
= Miniaturized cardiopulmonary bypass |
| ANP |
= Atrial natriuretic peptide |
|
NAC |
= N-acetylcysteine |
| ARBs |
= Angiotensin receptor blockers |
|
NGAL |
= Neutrophil gelatinase-associated lipocalin |
| BNP |
= Brain natriuretic peptide |
|
NMA |
= Network meta-analysis |
| CABG |
= Coronary artery bypass grafting |
|
NSAIDs |
= Nonsteroidal anti-inflammatory drugs |
| CCABs |
= Cell-cycle arrest biomarkers |
|
OPCAB |
= Off-pump coronary artery bypass |
| CI |
= Confidence interval |
|
OR |
= Odds ratio |
| CI-AKI |
= Contrast-induced acute kidney injury |
|
PRBC |
= Packed red blood cell |
| CIN |
= Contrast-induced nephropathy |
|
RCT |
= Randomised controlled trial |
| CKD |
= Chronic kidney disease |
|
RIFLE |
= Risk, Injury, Failure, Loss of kidney function, and |
| CPB |
= Cardiopulmonary bypass |
|
|
End-stage kidney disease |
| CSA-AKI |
= Cardiac surgery-associated acute kidney injury |
|
RIPC |
= Remote ischaemic preconditioning |
| CyC |
= Serum cystatin C |
|
ROS |
= Reactive oxygen species |
| EPO |
= Erythropoietin |
|
RR |
= Risk ratio |
| FDA |
= Food and Drug Administration |
|
RRT |
= Renal replacement therapy |
| GDT |
= Goal-directed therapy |
|
SCr |
= Serum creatinine |
| GFR |
= Glomerular filtration rate |
|
SIRS |
= Systemic inflammatory response syndrome |
| HES |
= Hydroxyethyl starch |
|
suPAR |
= Soluble urokinase plasminogen activator receptor |
| ICU |
= Intensive care unit |
|
TEA |
= Thoracic epidural analgesia |
| IGFBP7 |
= Insulin-like growth factor binding protein 7 |
|
TIMP2 |
= Tissue inhibitor of metalloproteinases-2 |